Compare ASTRAZENECA PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PFIZER - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PFIZER ASTRAZENECA PHARMA/
PFIZER
 
P/E (TTM) x 114.3 47.7 239.4% View Chart
P/BV x 35.0 7.9 441.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   PFIZER
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PFIZER
Mar-19
ASTRAZENECA PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2783,840 33.3%   
Low Rs8832,080 42.4%   
Sales per share (Unadj.) Rs228.4455.0 50.2%  
Earnings per share (Unadj.) Rs10.493.8 11.1%  
Cash flow per share (Unadj.) Rs16.3109.4 14.9%  
Dividends per share (Unadj.) Rs022.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs98.8658.2 15.0%  
Shares outstanding (eoy) m25.0045.75 54.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.76.5 72.7%   
Avg P/E ratio x104.231.6 330.2%  
P/CF ratio (eoy) x66.427.1 245.5%  
Price / Book Value ratio x10.94.5 243.2%  
Dividend payout %024.0 0.0%   
Avg Mkt Cap Rs m27,008135,420 19.9%   
No. of employees `0001.42.6 51.5%   
Total wages/salary Rs m1,5353,238 47.4%   
Avg. sales/employee Rs Th4,210.97,911.4 53.2%   
Avg. wages/employee Rs Th1,132.21,230.9 92.0%   
Avg. net profit/employee Rs Th191.11,630.7 11.7%   
INCOME DATA
Net Sales Rs m5,71020,815 27.4%  
Other income Rs m1231,674 7.3%   
Total revenues Rs m5,83322,489 25.9%   
Gross profit Rs m4635,712 8.1%  
Depreciation Rs m147714 20.6%   
Interest Rs m073 0.0%   
Profit before tax Rs m4386,599 6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,309 7.7%   
Profit after tax Rs m2594,291 6.0%  
Gross profit margin %8.127.4 29.5%  
Effective tax rate %40.835.0 116.8%   
Net profit margin %4.520.6 22.0%  
BALANCE SHEET DATA
Current assets Rs m3,20927,167 11.8%   
Current liabilities Rs m2,0708,917 23.2%   
Net working cap to sales %20.087.7 22.8%  
Current ratio x1.63.0 50.9%  
Inventory Days Days7268 106.7%  
Debtors Days Days3530 116.0%  
Net fixed assets Rs m7908,862 8.9%   
Share capital Rs m50458 10.9%   
"Free" reserves Rs m2,41929,656 8.2%   
Net worth Rs m2,46930,113 8.2%   
Long term debt Rs m025 0.0%   
Total assets Rs m4,60539,400 11.7%  
Interest coverage xNM91.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.5 234.7%   
Return on assets %5.611.1 50.8%  
Return on equity %10.514.2 73.6%  
Return on capital %17.722.1 80.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300428 69.9%   
Fx outflow Rs m2,015786 256.2%   
Net fx Rs m-1,715-358 479.0%   
CASH FLOW
From Operations Rs m88978 9.0%  
From Investments Rs m-94351 -26.7%  
From Financial Activity Rs mNA-1,099 0.0%  
Net Cashflow Rs m-6231 -2.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 15.7 4.9 320.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.7 38.4%  
Shareholders   12,856 85,207 15.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  AUROBINDO PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - SUVEN LIFE SCIENCES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS